Trials / Unknown
UnknownNCT03383237
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma：An Open-Label, Single-center, Single-arm Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.
Detailed description
Melanoma is a malignant tumor caused by hyperplasia of abnormal melanoma cells.Most of the adults above 30 years of age occur in the skin, mucosa and internal organs. The investigators designed the study to explore the possibility of apatinib as the Second-line Therapy in Malignant Melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | 500mg/d,q.d.,p.o. |
Timeline
- Start date
- 2017-11-29
- Primary completion
- 2018-11-01
- Completion
- 2019-11-01
- First posted
- 2017-12-26
- Last updated
- 2017-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03383237. Inclusion in this directory is not an endorsement.